The Latest

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

  • A sign reading Novo Nordisk is seen on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies

    The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help combat neurodegeneration.

  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis wins approval to use SMA gene therapy in older patients

    Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor function.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    Including J&J’s buyout of Halda Therapeutics, 13 company acquisitions have been announced since the start of October, the most active dealmaking stretch in several years.

    Updated Nov. 17, 2025
  • Trump Pfizer
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Pharma faces a critical ‘turning point’ in 2026, years in the making

    While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead scoops up a preclinical cancer program

    The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”

  • Illustration of a blood clot blocking red blood cells within an artery or a vein.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bayer’s experimental blood-thinner notches trial win in stroke prevention

    Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Including Evommune’s IPO Wednesday, only 10 biotechs have gone public in 2025, less than half the nearly two dozen that had priced offerings by this time last year.

    Updated Nov. 6, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Emerging biotech

    Biogen strikes deal with Versant-backed biotech to expand immune portfolio

    Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA probes effects of Takeda rare disease drug after patient death

    The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

  • Location of Delaware Court of Chancery in Wilmington
    Image attribution tooltip
    Mark Makela via Getty Images
    Image attribution tooltip

    GSK, Anaptysbio sue each other over Jemperli revenue

    As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Sofinnova Partners, which just closed a new fund, has been involved in five funding rounds since the start of October, two of which were announced over the last week.

    Updated Nov. 19, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M

    The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a megaround.

  • An illustration of a neuron cell network on a black background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A brain biotech’s top drug fails against MS

    Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for a drug that’s also piqued Johnson & Johnson’s interest.

  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna secures $1.5B lifeline as it looks to break even in 2028

    At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth in 2027 and 2028.”

  • Modern glass and metal office building with a reflective blue-tinted facade, set against a clear blue sky. In the foreground, a large black and white sign reads “Abbott” with the company’s stylized logo and the number “645.” The area has neatly cut grass and a few small trees.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Abbott to acquire Exact Sciences for about $21B

    The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.

  • A neurodegenerative disease concept illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Aspen raises $115M for a Parkinson’s stem cell treatment

    The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the neurodegenerative condition, as well as plans for building its manufacturing capabilities.

  • A sign spelling Roche hangs on the side of a building.
    Image attribution tooltip
    Sedat Suna via Getty Images
    Image attribution tooltip

    Roche inks deal for rights to Freenome cancer tests outside US

    Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round.

  • FDA
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    With new approvals, Regeneron’s higher-dose Eylea gets more competitive

    Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

  • Single strand ribonucleic acid, RNA research
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    RNAi biotech Arrowhead wins first FDA approval

    The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a commercial-stage company and sets up a turf war with Ionis Pharmaceuticals.

    Updated Nov. 18, 2025
  • Image attribution tooltip
    Jonathan Gardner/BioPharma Dive
    Image attribution tooltip

    Agios shares fall on mixed sickle cell results for blood disease drug

    Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention as a rare disease specialist.

  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zymeworks to change course, pursue ‘royalty-driven’ biotech model

    On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a new strategy its CEO says will create “more consistent value for shareholders.”

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Alkermes escalates bidding war; US biotech risks ‘falling behind’ China

    A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

  • Merck sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck’s blockbuster-to-be cardiovascular drug scores in another heart study

    Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.

  • Close up of Scott Gottlieb wearing a suit and tie
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    UnitedHealth adds former FDA commissioner Scott Gottlieb to board

    The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal regulators.

    FDA